Moreover, we report that TpeL is capable of inhibiting the Raf-MEK-ERK pathway in NRAS mutant melanoma cells, which are paradoxically activated by the B-Raf kinase inhibitor Vemurafenib, indicating an essential role of Ras in this activation. This evidence concerns the gene RAF1 and melanoma.